CDMO outperforms, formulations stumble; Zambia set to uplift FY28

CDMO revenue ₹964 Cr, +18.6% YoY, driven by volume and API price recovery

Domestic branded +7.3% YoY, Int'l branded -1.5% YoY; below prior double-digit export guidance

Q1 margins 15.0%, but CFO confirmed driven by high API prices and Q4 inventory buildup—temporary drivers

EBITDA -₹4 Cr (vs -₹6 Cr Q1 FY26, -₹12 Cr Q4 FY26); losses trending down but still negative

100+ products agreed with government, advanced stages, revenue recognition FY27 (updated from Q2 start to Q3/Q4)

Prior call implied Q2 start; now Q3/Q4. Still ~₹240 Cr H2 FY27 and FY28 at higher-teen margin (vs prior 15–17%).

Reaffirm 14–15% but management caveated: Q1 benefited from one-time inventory gains and elevated API prices. Forward bias to upper bracket conditional on these staying.

Prior: double-digit export growth. Q1 delivered: Int'l branded -1.5%. Domestic 7% (vs IPM ~2–3% + launches, implying management expected higher).

Q2 high-teens volumes. API prices volatile, moving upward. Margins target 14–15%, Q1 strong allows bias to upper bracket.

API prices high; Q4 inventory buildup was strategic for margin protection. Both are tactical moves.

Akumentis: added 200 field, focused on Rx (gynaecology, cardiology, peds). Unosource: focus markets strategy, niche portfolio.

Akumentis: EBITDA drain from 200 field hires (15% increase, no PCPM yet). Unosource: one muted quarter; recovery Q2–Q3.

High-teens Q3–Q1; Q2 strong high-teens. IPM 2–3%, volume is key lever. At least double-digit growth coming quarters.

Mix of launches, price, volume. Already taken price growth this quarter.

Fully confident, 3–4 years invested, losses coming down. Question is how to improve profitability and scale, not exit.

Zambia/Europe: similar to current CDMO, maybe higher (higher teens). $25M (~₹240 Cr) H2 FY27, similar FY28. Spare capacity strategic; can do 55–60%, now at 50%.

Company well-run by professionals. Always need fresh blood but ample leadership. Stem from homegrown talent.

Sandeep denied; said have M.Pharms, PhDs, doctorates, best % in industry. Andrey persisted: feedback from shareholders and ex-employees.

Maintained Q3, maybe some Q4. Advanced stages with 100+ products. This fiscal will recognize revenue.

Yes, net of debt.

Niche formulation strategy. Expand cosmeceutical capacity, venture into color cosmetics. Build on R&D moat. Tap fast-growing BPC market.

No subcontracting. Gross margins >40%, don't want to lose. Business via basket approach. Setting up Baddi facility by year-end for oral boost.

Very limited inventory gains. Mostly high-value products. API also improved (90%+ COGS → 75% COGS).

Yes, expectation. API and CDMO improvements supporting.

No seasonality. Completely in control. Expected to gradually come down toward breakeven.

Difficult to quantify. Industry sustains. Expect at least double digits FY27/FY28. Baddi capacity by year-end supports future.

Have ₹1,600 Cr cash, non-leveraged. Look at value accretion and business rationale. Cautious on very large bids, but have ammunition.

Cost-plus model—input material prices passed at each PO. Inventory behavior varies by customer. 5–6 months into inflation, secondary market picking up, volume still growing.

Yes. Target monthly EBITDA positive by end Feb/March, then next year positive P&L contribution.

98% in fixed deposits, nationalized banks. No debt, net worth >₹3,400 Cr. Will pursue acquisitions if synergies, else secured for business.

Lower than average, correct. Strategy: strong clinical presence, focused products. Expansion for geographies/HQs. PCPM is mature metric; they're in build phase. Will eventually reach/surpass industry but in investment mode.

Q2 already 'extremely encouraging'; volumes sustained; API prices moving upward. Precedent: Q3–Q4 FY26, Q1 FY27 all high-teens.

100+ products finalized with government; advanced stages. Expected Q3 or some Q4 revenue recognition this fiscal.

Pilots underway; no specific revenue quantum yet; timeline next FY only.

Q1 at 15% but management caveated: API prices high, Q4 inventory buildup tactical. If prices normalize, 14% risk.

Vaguer than prior '15–17%' range. CDMO margins currently ~16.9% (₹163/₹964); 'higher teens' suggests 18–19%.

Announced; expected to 'significantly boost oral manufacturing capabilities' but capex quantum not disclosed ('still discussing').

15% margin driven by high API prices and Q4 inventory buildup for protection. If API prices normalize (management acknowledged volatility) or inventory liquidates, margins could compress to 14% or below.

Domestic branded revenue +7.3% YoY but EBITDA fell 25% due to 200 new field staff (15% increase). International branded fell 1.5% YoY. Both missed prior double-digit export guidance; recovery delayed to Q3.

CDMO is ₹964 Cr (82.7% of total revenue). No breakdown of customer concentration disclosed. Loss of major customer would materially impact revenue and profitability.

API EBITDA -₹4 Cr (improving from -₹6 Cr Q1 FY26, -₹12 Cr Q4 FY26), but target is monthly breakeven by end FY27. Losses must halve again in one quarter for target; execution risk remains.

Zambia order pushed from Q2 start to Q3/Q4 revenue recognition. ₹240 Cr (≈$25M) expected in H2 FY27, but no revenue yet. Supply chain delays or regulatory friction could slip to next year.

Analyst (Andrey) surfaced feedback from minority shareholders and ex-employees that many staff are 12th-class pass, potentially limiting execution quality. Management denied but defensive tone.